share_log

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Clearmind Medicine | 6-K：外国发行人报告
美股sec公告 ·  04/30 16:22
Moomoo AI 已提取核心信息
Clearmind Medicine Inc., a clinical-stage biotech company, announced on April 30, 2024, its intention to apply for an order to cease being a reporting issuer in the Canadian provinces of British Columbia, Ontario, and Alberta. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents with Canadian Securities Regulators. Despite this change, Clearmind will continue to meet disclosure obligations in the United States and Germany, adhering to the laws and regulations of the U.S., the Nasdaq, and the Frankfurt Stock Exchange. The company's continuous disclosure documents will remain accessible to all shareholders on its website, and Canadian shareholders will receive these documents concurrently with U.S. and German shareholders. Clearmind, which specializes in developing psychedelic-derived therapeutics for major health issues like alcohol use disorder, has a portfolio of seventeen patent families and trades on Nasdaq and the FSE under the symbols 'CMND' and 'CWYO', respectively. The company had previously voluntarily delisted from the Canadian Securities Exchange as of March 14, 2024.
Clearmind Medicine Inc., a clinical-stage biotech company, announced on April 30, 2024, its intention to apply for an order to cease being a reporting issuer in the Canadian provinces of British Columbia, Ontario, and Alberta. If approved, the company will no longer be required to file financial statements and other continuous disclosure documents with Canadian Securities Regulators. Despite this change, Clearmind will continue to meet disclosure obligations in the United States and Germany, adhering to the laws and regulations of the U.S., the Nasdaq, and the Frankfurt Stock Exchange. The company's continuous disclosure documents will remain accessible to all shareholders on its website, and Canadian shareholders will receive these documents concurrently with U.S. and German shareholders. Clearmind, which specializes in developing psychedelic-derived therapeutics for major health issues like alcohol use disorder, has a portfolio of seventeen patent families and trades on Nasdaq and the FSE under the symbols 'CMND' and 'CWYO', respectively. The company had previously voluntarily delisted from the Canadian Securities Exchange as of March 14, 2024.
处于临床阶段的生物技术公司Clearmind Medicine Inc. 于2024年4月30日宣布，打算申请一项命令，停止在加拿大不列颠哥伦比亚省、安大略省和艾伯塔省担任报告发行人。如果获得批准，公司将不再需要向加拿大证券监管机构提交财务报表和其他持续披露文件。尽管有这一变化，Clearmind将继续履行美国和德国的披露义务，遵守美国、纳斯达克和法兰克福证券交易所的法律法规。该公司的持续披露文件将可供所有股东在其网站上查阅，加拿大股东将与美国和德国股东同时收到这些文件。Clearmind专门为酒精使用障碍等重大健康问题开发迷幻药衍生疗法，拥有十七个专利家族，在纳斯达克和富时证券交易所上市，交易代码分别为 “CMND” 和 “CWYO”。截至2024年3月14日，该公司已自愿从加拿大证券交易所退市。
处于临床阶段的生物技术公司Clearmind Medicine Inc. 于2024年4月30日宣布，打算申请一项命令，停止在加拿大不列颠哥伦比亚省、安大略省和艾伯塔省担任报告发行人。如果获得批准，公司将不再需要向加拿大证券监管机构提交财务报表和其他持续披露文件。尽管有这一变化，Clearmind将继续履行美国和德国的披露义务，遵守美国、纳斯达克和法兰克福证券交易所的法律法规。该公司的持续披露文件将可供所有股东在其网站上查阅，加拿大股东将与美国和德国股东同时收到这些文件。Clearmind专门为酒精使用障碍等重大健康问题开发迷幻药衍生疗法，拥有十七个专利家族，在纳斯达克和富时证券交易所上市，交易代码分别为 “CMND” 和 “CWYO”。截至2024年3月14日，该公司已自愿从加拿大证券交易所退市。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息